Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Diovan Enjoys Steady Growth, Sales of \60 Bil. in 2003
January 19, 2004
- REGULATORY NEWS IN BRIEF
January 19, 2004
- IMS Japan Aims to Become a Services-based Company: President Saeki
January 12, 2004
- ON THE MOVE
January 12, 2004
- Time to New Drug Approval Down Sharply Since Mid-90s: OPIR
January 12, 2004
- Test Kit to Be Developed to Predict Effects of Morphine
January 12, 2004
- BUSINESS NEWS IN BRIEF
January 12, 2004
- RA Patients Criticized as Selfish, Lazy: Wyeth Survey
January 12, 2004
- BULLETIN
January 12, 2004
- Pharmacokinetic Frequency Analysis Database Jointly Developed by PSC, JBIC
January 12, 2004
- FJPWA Petitions Korosho Regarding Joint Purchasing
January 12, 2004
- DIAGNOSTIC NEWS IN BRIEF
January 12, 2004
- Council Supports Inspection, Payment of Dispensing Bills by Insurers
January 12, 2004
- MEDICAL DEVICE NEWS IN BRIEF
January 12, 2004
- Monkasho Facing 4.5% Budget Cut in FY2004
January 12, 2004
- JACDS to Create Certification System for Kampo Advisors
January 12, 2004
- NEW PRODUCTS
January 12, 2004
- Semi-annual Business Results
January 12, 2004
- Korosho Starts General Review of Post-Marketing Safety Policies
January 12, 2004
- Funding for Disease Measures Up Slightly in Korosho's FY2004 Budget
January 12, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…